{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-nausea-vomiting/prescribing-information/prescribing-an-anti-emetic/","result":{"pageContext":{"chapter":{"id":"f61e929d-def9-58db-877e-a030bc91d3de","slug":"prescribing-an-anti-emetic","fullItemName":"Prescribing an anti-emetic","depth":2,"htmlHeader":"<!-- begin field 1ce56f09-f134-4ad8-955e-5e05c3339202 --><h2>Prescribing an anti-emetic</h2><!-- end field 1ce56f09-f134-4ad8-955e-5e05c3339202 -->","summary":"","htmlStringContent":"<!-- begin item da8f3d56-059e-40c1-9304-c3a047a1223c --><!-- end item da8f3d56-059e-40c1-9304-c3a047a1223c -->","topic":{"id":"8a2e6dd8-7d6f-5fcf-a744-1b12e2a14232","topicId":"329a162f-132a-4d7e-afd5-7ff2f86369d2","topicName":"Palliative care - nausea and vomiting","slug":"palliative-care-nausea-vomiting","lastRevised":"Last revised in October 2020","chapters":[{"id":"4cf6ed2e-fa29-54e9-8d93-4bd52407c5c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2e3a3e75-af78-5547-a042-7aa68a341672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"27d24f4a-dbc8-560f-b100-ca5287022d66","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b433057a-92f0-5457-837c-f3f7235e44e6","slug":"changes","fullItemName":"Changes"},{"id":"540b41fe-3e71-5c29-9379-7493711a8a59","slug":"update","fullItemName":"Update"}]},{"id":"ed201382-7c29-58e9-ba5d-f5c415eb3bf3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7043600f-13dd-5980-b06d-73dab2266896","slug":"goals","fullItemName":"Goals"},{"id":"63b87fa3-3c3d-527b-9ac2-e856dd0c559e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3ee330-3c0d-5735-b8d5-76b606865d07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d1227949-2a90-5b29-abef-3895e05333c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e2e036e5-217a-593d-947f-a8376f0f5e98","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3885ba7b-9d6f-5262-a541-463284363660","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b65bec71-2fa0-54e0-be57-13a917c2a697","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a9561403-d5a9-5c9c-b6e6-c24410e9d9d3","slug":"definition","fullItemName":"Definition"},{"id":"d92b4aee-031c-58a4-b4b9-5d13767e0261","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b1327253-7b93-5a44-b2f7-5e002ae90e8f","slug":"causes","fullItemName":"Causes"},{"id":"e321f36e-5ec2-5074-b128-109efef69a65","slug":"complications","fullItemName":"Complications"}]},{"id":"a4a81f08-7894-5ba4-a4e5-c5505f3e5250","fullItemName":"Management","slug":"management","subChapters":[{"id":"8691c12d-3ed6-5e16-bef3-667d198f6707","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"e2566bf0-9d82-5bc7-9b5f-835384f56bc2","slug":"known-cause","fullItemName":"Scenario: Known cause"},{"id":"c8237819-4755-5cd8-ad7c-12735068c87a","slug":"unknown-cause","fullItemName":"Scenario: Unknown cause"},{"id":"145fe4aa-682c-5299-9906-a7bca2e98a9b","slug":"end-of-life","fullItemName":"Scenario: End of life"}]},{"id":"4d9745dc-8b36-500d-8e94-0e51611a4373","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f61e929d-def9-58db-877e-a030bc91d3de","slug":"prescribing-an-anti-emetic","fullItemName":"Prescribing an anti-emetic"},{"id":"d39c4487-f9dc-5d1d-be98-95561ca991bd","slug":"prescribing-a-prokinetic","fullItemName":"Prescribing a prokinetic"},{"id":"23e74db2-9671-539b-8bcf-b5c4bdff23f9","slug":"prescribing-haloperidol","fullItemName":"Prescribing haloperidol"},{"id":"00a2a0a3-8bc1-5d27-a03f-6cd4624d1c38","slug":"prescribing-levomepromazine","fullItemName":"Prescribing levomepromazine"},{"id":"d0437d3a-566f-5df2-9800-1961ed4664e8","slug":"prescribing-cyclizine","fullItemName":"Prescribing cyclizine"},{"id":"e6d5c2a8-e2b8-55c5-afd4-46f2edcd4a30","slug":"prescribing-dexamethasone","fullItemName":"Prescribing dexamethasone"},{"id":"3042d096-a74b-5c66-8d18-8c233091e783","slug":"prescribing-hyoscine-butylbromide","fullItemName":"Prescribing hyoscine butylbromide"}]},{"id":"ba414d8a-38a1-5962-84ab-6051ffe6dfe9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"26e42d0a-9ee9-50c5-9f2b-818da289f6e9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c0795c41-1865-5ab1-b820-e41b8b5d9aab","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3076afc1-a703-524e-9ec9-995b34c4d386","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"08b8fc57-db22-518d-a528-777cb4e8d7dc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81928ac1-4f26-5da9-b11f-85d1cee4fbdd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5aee10d5-2771-547a-a52a-1fb430319da3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3cfa53b2-3d63-508d-80ea-c2a6293844fc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4d9745dc-8b36-500d-8e94-0e51611a4373","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d1d8fb0e-5346-5147-8881-044daa4090df","slug":"route-of-administration","fullItemName":"Route of administration","depth":3,"htmlHeader":"<!-- begin field f6dfdff8-49fd-4d6f-ae9c-b90b12654bf2 --><h3>What route of administration should I use?</h3><!-- end field f6dfdff8-49fd-4d6f-ae9c-b90b12654bf2 -->","summary":"","htmlStringContent":"<!-- begin item b1b30435-15c5-4452-952a-6e1c56fc5d43 --><!-- begin field 9ae9042d-6ea2-443e-b8bf-95557d5a577d --><ul><li><strong>Oral administration is the route of choice. </strong>However, this may not be appropriate for people:<ul><li>Who cannot swallow.</li><li>With compromised absorption.</li><li>Who have persistent nausea and vomiting.</li><li>In whom swallowing causes them to vomit.</li><li>With gastric stasis or bowel obstruction.</li></ul></li><li>If the oral route is not appropriate, give anti-emetics parenterally (subcutaneously or intravenously) or rectally. The intramuscular route is not recommended as people with advanced cancer tend to be cachectic.</li><li>If the person has continuous or severe nausea or frequent vomiting, continuous subcutaneous infusion via a syringe driver is the route of choice.<ul><li>Continuous subcutaneous infusion (via a syringe driver) is used for drug delivery if the person cannot take medicines by mouth (for example because of persistent nausea and vomiting, dysphagia, severe weakness, poor oral absorption, or coma).</li><li>Use only drugs that are known to be safe and effective by the subcutaneous route. These include metoclopramide, haloperidol, cyclizine, hyoscine butylbromide, and levomepromazine.</li><li>Use water for injection as the diluent when mixing drugs in a syringe driver (except for octreotide).</li><li>Use sodium chloride as the diluent for octreotide and consider a second syringe driver if octreotide is to be co-administered with other drugs.</li><li><strong>Before mixing drugs, check their compatibility.</strong><ul><li>Always follow local palliative care guidelines or seek advice from local palliative care services or hospital pharmacy drug information services before mixing drugs in a syringe driver.</li><li>Data are most often available on combinations of two drugs in a syringe driver, although some combinations of three or four drugs are compatible.</li><li>If you cannot contact the appropriate authorities for further guidance, see <a href=\"http://www.palliativedrugs.com/syringe-driver-database-introduction.html\" data-hyperlink-id=\"989da39d-43d9-441d-8517-a98f00366684\">www.palliativedrugs.com/syringe-driver-database-introduction.html</a> (registration required).</li></ul></li><li><strong>Do not use solutions that are discoloured or have precipitated.</strong></li></ul></li><li>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Perdue, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>] and palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</li></ul><!-- end field 9ae9042d-6ea2-443e-b8bf-95557d5a577d --><!-- end item b1b30435-15c5-4452-952a-6e1c56fc5d43 -->","subChapters":[]},{"id":"81ff4b03-dc39-57d8-9dd5-51574c9bc99b","slug":"anti-emetics-in-conjunction-with-opioids","fullItemName":"Anti-emetics in conjunction with opioids","depth":3,"htmlHeader":"<!-- begin field db957d5c-5bcd-471d-88fb-fb5a28a0ac07 --><h3>How should I prescribe an anti-emetic in conjunction with an opioid?</h3><!-- end field db957d5c-5bcd-471d-88fb-fb5a28a0ac07 -->","summary":"","htmlStringContent":"<!-- begin item fca47e61-1384-4f32-9b42-8dd063c3d72f --><!-- begin field 02bf0ce0-7f99-4c1c-9493-fbc8396aed6a --><ul><li>When starting an opioid, prescribe an anti-emetic (for example haloperidol or metoclopramide):<ul><li>Regularly for the first week, to prevent opioid-induced nausea and vomiting if the person has experienced nausea with a previous opioid,<em>or</em></li><li>On standby, for use on an as-required basis for one week, in case the person experiences nausea with morphine but has <em>not </em>experienced nausea with a previous opioid.</li></ul></li></ul><ul><li>This recommendation is based on palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>] and published journal articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Mannix, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Laugsand et al, 2011</a>].</li><li>Nausea at introduction of opioids occurs in about 30% of people; however, tolerance to nausea occurs within 2 weeks of starting the opioid [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Mannix, 2006</a>].</li><li>Evidence from a review article suggests that the risk of opioid-induced nausea and vomiting in people with advanced cancer may be reduced by changing the opioid or its route of administration. However, the authors concluded that the evidence was too limited to prioritize between symptomatic treatment of the nausea and vomiting and adjustment of the opioid treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Laugsand et al, 2011</a>].</li></ul><!-- end field 02bf0ce0-7f99-4c1c-9493-fbc8396aed6a --><!-- end item fca47e61-1384-4f32-9b42-8dd063c3d72f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}